57915-79-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,3-Dichlorophenyl)propionic acid is used as an anti-inflammatory agent for the treatment of various conditions characterized by pain and inflammation, such as arthritis and menstrual cramps. It is effective in reducing the production of prostaglandins, which are the primary mediators of these symptoms.
Used in Pain Management:
Diclofenac serves as an analgesic, helping to alleviate pain associated with musculoskeletal disorders, rheumatoid arthritis, and osteoarthritis. Its ability to inhibit prostaglandin synthesis contributes to its efficacy in pain relief.
Used in Topical Treatments:
In the form of topical gels, 3-(2,3-Dichlorophenyl)propionic acid is used for localized treatment of inflammation and pain, providing a targeted approach to symptom management without the systemic side effects that may accompany oral administration.
Used in Medical Supervision:
Due to the potential for side effects, 3-(2,3-Dichlorophenyl)propionic acid is used under the guidance of healthcare professionals. This ensures that the benefits of the drug are maximized while minimizing the risk of adverse reactions.

InChI:InChI=1/C9H8Cl2O2/c10-7-3-1-2-6(9(7)11)4-5-8(12)13/h1-3H,4-5H2,(H,12,13)

Upstream product

• 69426-58-0 methyl 3-(2,3-dichlorophenyl)propionate 
• 608-27-5 2,3-dichloroaniline 
• 20595-44-2 3-(2,3-dichlorophenyl)acrylic acid 
• 69392-62-7 methyl 2-bromo-3-(2,3-dichlorophenyl)propionate 

Downstream Products

• 1449767-10-5 3-(2,3-dichlorophenyl)-N-(5,6-dihydrothiazolo[2,3-c][1,2,4]-triazol-3-yl)propionamide 
• 69426-58-0 methyl 3-(2,3-dichlorophenyl)propionate 
• 69392-64-9 4,5-dichloroindan-1-one 
• 73075-66-8 1,2-Dichloro-3-(2-isocyanato-ethyl)-benzene 
• 73075-67-9 5,6-dichloro-3,4-dihydro-1(2H)-isoquinolinone 
• 69392-63-8 3-(2,3-dichloro-phenyl)-propionyl chloride 

Relevant academic research and scientific papers

NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

Derivatives of 5H, 10H-imidazo[1, 2-a]indeno[1,2-e]pyrazin-4-one, preparation thereof and medicaments containing them

Compounds having the formula (I) wherein R and R 1, similar or different, represent a hydrogen or halogen atom or a radical alkyl, alkoxy, amino, acylamino, phenylureido, --N CH--N(R 2)R 3, nitro, imidazolyl, phenyl, SO 3 H or cyano; R 2 and R 3 which may

Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis: I. Chloro-substituted 1,2,3,4-tetrahydroisoquinolines

In a search for inhibitors of epinephrine biosynthesis as potential therapeutic agents, a series of 13 ring-chlorinated 1,2,3,4-tetrahydroisoquinolines was prepared. These compounds were tested initially for their ability to inhibit rabbit adrenal phenylethanolamine N-methyltransferase (PNMT) in vitro. Enzyme-inhibitor dissociation constants, determined for the six most potent members of the series, indicated the following order of decreasing potency: 7,8-Cl2>6,7,8-Cl3>7-Cl~8-Cl>5,6,7,8-Cl4>5,7,8-Cl3. These compounds were subsequently examined for PNMT-inhibiting activity in intact rats and mice. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (SK&F 64139) was the most potent member of the series both in vitro and in vivo and is currently undergoing clinical investigation.

4 AND 5-Halo substituted 2-indanamine compounds

2-Indanamine compounds having 4 and 5-halo substituents are inhibitors of phenylethanolamine N-methyltransferase.